1. [CASE 1 — QUESTION 1] A 42-year-old woman presents to the emergency department with acute abdomen requiring emergency exploratory laparotomy. Her past medical history is significant for a positive caffeine-halothane contracture test confirming malignant hyperthermia (MH) susceptibility, performed after her brother suffered an MH crisis during a cholecystectomy. She has no other medical conditions. She last ate 6 hours ago. Her vital signs are stable. The surgeon is ready and the anesthesiologist must perform rapid sequence intubation. Which of the following is the most appropriate neuromuscular blocking agent for RSI in this patient?

• A) Succinylcholine 1.5 mg/kg — the MH susceptibility of this patient is relative rather than absolute, and the urgency of the emergency laparotomy justifies its use; the onset speed of succinylcholine is unmatched and the brief 8 to 12 minute duration limits total volatile trigger exposure.
• B) Vecuronium 0.2 mg/kg — doubling the standard intubating dose of vecuronium to 0.2 mg/kg reduces its onset from the usual 3 to 4 minutes to approximately 60 to 90 seconds through enhanced receptor occupancy, providing RSI-equivalent conditions without triggering agents; it is preferred over rocuronium because vecuronium's smaller volume of distribution produces a higher initial peak NMJ concentration.
• C) Rocuronium 1.2 mg/kg with sugammadex 16 mg/kg drawn up and immediately available — succinylcholine is absolutely contraindicated in confirmed MH susceptibility because it is an established MH triggering agent; rocuronium at the RSI dose achieves intubating conditions within 45 to 60 seconds comparable to succinylcholine, and the immediately available sugammadex 16 mg/kg provides reversal within approximately 3 minutes if intubation fails, eliminating any scenario in which a triggering agent is needed.
• D) Cisatracurium 0.4 mg/kg — this high dose of cisatracurium achieves faster onset than the standard 0.15 mg/kg by mass-action receptor saturation, and its benzylisoquinolinium structure carries no MH triggering risk; as a non-triggering non-depolarizing agent it is both safe and effective for RSI in MH-susceptible patients.
• E) Mivacurium 0.25 mg/kg — mivacurium's short clinical duration of 12 to 20 minutes is ideal for emergency intubation in MH-susceptible patients because if intubation fails, the block resolves spontaneously within minutes without pharmacological reversal; its benzylisoquinolinium structure carries no MH triggering risk.

2. [CASE 1 — QUESTION 2] Continuing with the same patient. Rocuronium 1.2 mg/kg was successfully administered and intubation was achieved in 55 seconds. Total intravenous anesthesia with propofol is being used throughout. Forty-five minutes into the procedure, the surgeon requests complete muscular relaxation for a difficult dissection near the inferior mesenteric artery. Train-of-four monitoring shows count of 0 with post-tetanic count (PTC) of 1, confirming profound block is present. At the end of the case 35 minutes later, the surgeon is closing and the anesthesiologist prepares to reverse neuromuscular block. Which reversal agent and dose correctly addresses the depth of block at this point?

• A) Sugammadex 16 mg/kg — the PTC of 1 at the time of the deepest block, combined with 35 minutes of additional spontaneous partial recovery during closure, means the block is now in the deep range (TOF count 0, PTC ≥2) requiring sugammadex 4 mg/kg at minimum; however, because the rocuronium RSI dose of 1.2 mg/kg was used and residual drug from this large dose may still maintain profound levels despite elapsed time, sugammadex 16 mg/kg is the safe and appropriate dose to guarantee full reversal to TOF ratio above 0.9; neostigmine has no role here under any circumstances.
• B) Neostigmine 0.07 mg/kg with glycopyrrolate — rocuronium is a non-depolarizing agent and neostigmine is the standard reversal agent for non-depolarizing block; at the maximum dose of 0.07 mg/kg, neostigmine generates sufficient acetylcholine to competitively displace rocuronium from end-plate receptors regardless of block depth when the drug is an aminosteroid.
• C) Sugammadex 2 mg/kg — this is the standard dose for reversal of moderate block (TOF count ≥2); because 35 minutes have elapsed since the PTC of 1 was recorded and spontaneous recovery has been occurring, the block has likely recovered to at least the moderate range, making 2 mg/kg appropriate without remeasurement.
• D) No reversal agent is needed — rocuronium 1.2 mg/kg was given over 90 minutes ago and the drug's clinical duration at this dose is 60 to 90 minutes; spontaneous recovery to a TOF ratio above 0.9 is expected to be complete at this point, and administering any reversal agent after spontaneous full recovery risks recurarization paradox from displacement of the cyclodextrin complex.
• E) Sugammadex 4 mg/kg followed by neostigmine 0.05 mg/kg 5 minutes later — combination reversal is required after rocuronium 1.2 mg/kg because the high initial dose means more drug was distributed to deep tissue compartments; sugammadex alone cannot access these deep compartments and neostigmine is needed to prevent recurarization from redistribution of tissue-bound rocuronium back to the NMJ.

3. [CASE 1 — QUESTION 3] Continuing with the same patient. The anesthesiologist's colleague asks why neostigmine cannot be used to reverse the rocuronium block in this patient, even at the maximum dose of 0.07 mg/kg. Which of the following best explains the pharmacological ceiling effect that limits neostigmine's utility at deep levels of neuromuscular block?

• A) Neostigmine's ceiling effect at deep block is due to its rapid elimination — at deep block levels, the large amount of rocuronium present means neostigmine is consumed faster than it can be replenished, and plasma neostigmine concentrations fall below the threshold for acetylcholinesterase inhibition before sufficient acetylcholine accumulates to compete with the remaining rocuronium.
• B) Neostigmine is limited at deep block because it directly competes with rocuronium for the same allosteric site on the nicotinic receptor alpha subunit; at high levels of rocuronium receptor occupancy, the allosteric site is saturated and neostigmine cannot gain access to exert its effects regardless of dose.
• C) Neostigmine's ceiling effect reflects its action on the wrong enzyme — at deep block, acetylcholinesterase is present in sufficient quantity that even complete inhibition by neostigmine cannot produce a clinically meaningful increase in synaptic acetylcholine concentration; the rate-limiting step is acetylcholine synthesis rather than breakdown, and neostigmine cannot accelerate synthesis.
• D) Neostigmine cannot reverse deep block because its muscarinic side effects — bradycardia and bronchospasm — become prohibitively severe at the higher doses that would be required to overcome high levels of rocuronium receptor occupancy; the dose-limiting toxicity prevents achieving the plasma concentration needed for deep block reversal.
• E) Neostigmine works by inhibiting acetylcholinesterase to raise synaptic acetylcholine concentration, relying on the increased acetylcholine to competitively displace rocuronium from nicotinic receptors; this mechanism has a pharmacological ceiling because the maximum achievable synaptic acetylcholine concentration is limited by the rate of synthesis and vesicular release — at deep block levels where rocuronium receptor occupancy approaches 95% or more, even this maximal acetylcholine concentration is insufficient to displace enough rocuronium to restore functional neuromuscular transmission, making neostigmine ineffective regardless of dose.

4. [CASE 1 — QUESTION 4] Continuing with the same patient. Sugammadex 16 mg/kg was administered at closure and the patient was extubated 8 minutes later. In the post-anesthesia care unit, the anesthesiologist reviews the case with a resident and emphasizes the importance of quantitative neuromuscular monitoring. The resident asks why clinical signs such as head lift and grip strength are insufficient to confirm complete neuromuscular recovery before extubation. Which of the following best explains the limitation of clinical assessment and the rationale for quantitative TOF monitoring?

• A) Clinical signs of neuromuscular recovery — head lift, grip strength, and tongue protrusion — are sensitive but not specific; they confirm the absence of deep block but cannot distinguish between TOF ratios of 0.7 and 0.9, both of which produce identical clinical appearances but have very different pharyngeal muscle function profiles; quantitative monitoring is needed to detect the difference.
• B) Clinical signs of neuromuscular recovery are unreliable because they primarily reflect diaphragmatic and limb muscle function — muscles that are resistant to partial neuromuscular block and can perform their tasks at TOF ratios well below 0.9; pharyngeal dilator, upper esophageal sphincter, and laryngeal adductor muscles are significantly more sensitive to residual block and lose coordinated function at TOF ratios between 0.7 and 0.9, a range in which the patient may appear able to sustain head lift and have a measurable grip yet have critically impaired airway protection; only quantitative TOF ratio measurement detects this dangerous dissociation.
• C) Clinical signs are unreliable after sugammadex reversal specifically — sugammadex produces a transient overshoot of TOF ratio above 1.0 in some patients, creating false clinical signs of full recovery while actual receptor occupancy remains at 10 to 15%; quantitative monitoring detects this overshoot and ensures the TOF ratio has normalized to the 0.9 to 1.0 range before extubation is attempted.
• D) Clinical neuromuscular assessment is validated only for non-depolarizing agents reversed with neostigmine; after sugammadex reversal of rocuronium, the cyclodextrin-rocuronium complex can dissociate in alkaline urine and the released rocuronium may produce recurrent block that presents as isolated pharyngeal weakness before any clinical signs become apparent.
• E) Head lift duration of 5 seconds has been validated as a reliable indicator of TOF ratio above 0.9 in all published studies; however, this test cannot be performed in patients who are still sedated or have residual opioid analgesia, which is the case for most post-operative patients; quantitative monitoring is preferred because it does not require patient cooperation.

5. [CASE 2 — QUESTION 1] An 8-year-old, 26 kg boy presents for elective tonsillectomy. He has no relevant medical history and a normal preoperative assessment. The pediatric anesthesiologist induces anesthesia with sevoflurane and administers succinylcholine 2 mg/kg intravenously for intubation without atropine pretreatment. Within 60 seconds, his heart rate drops from 110 to 38 beats per minute. Which of the following correctly identifies the mechanism responsible for this bradycardia and explains why children are particularly susceptible?

• A) The bradycardia reflects succinylcholine-induced Phase I depolarizing block of sinoatrial node nicotinic receptors — cardiac pacemaker cells express a low density of fetal-type nAChRs that are activated by succinylcholine at intubating doses; in children the higher proportion of fetal-type receptors in the conduction system amplifies this direct chronotropic effect.
• B) The bradycardia is caused by the potassium efflux associated with succinylcholine-induced end-plate depolarization — in children with higher muscle mass relative to total body water compared to adults, the 0.5 mEq/L potassium rise per kilogram of muscle is magnified, producing serum potassium levels sufficient to slow sinus node automaticity through membrane hyperpolarization.
• C) The bradycardia results from succinylcholine-mediated histamine release activating H2 receptors in the sinoatrial node — in children, mast cell density around cardiac conduction tissue is higher than in adults and succinylcholine triggers more histamine release per milligram of drug at pediatric dosing, producing a direct negative chronotropic effect through H2-mediated cAMP suppression.
• D) Succinylcholine and its metabolite succinylmonocholine stimulate cardiac muscarinic M2 receptors in the sinoatrial node, producing parasympathomimetic slowing of heart rate; this effect is most pronounced in children because they have higher baseline vagal tone than adults and a lower sympathetic-to-parasympathetic balance; the effect is characteristically more severe with a second dose because succinylmonocholine — which accumulates with repeat dosing and has greater muscarinic relative to nicotinic activity — reaches higher concentrations; prophylactic atropine before succinylcholine is standard practice in pediatric protocols to prevent this response.
• E) The bradycardia is caused by succinylcholine-induced transient hypotension from peripheral vasodilation — at the pediatric dose of 2 mg/kg, succinylcholine releases sufficient histamine from peripheral mast cells to reduce systemic vascular resistance acutely; the resulting baroreceptor-mediated vagal surge slows heart rate as a compensatory reflex; the mechanism is age-independent but more pronounced when the relative dose per body weight is higher.

6. [CASE 2 — QUESTION 2] Continuing with the same patient. Atropine 0.4 mg was administered and the heart rate recovered to 98 bpm. Intubation was successful. Sevoflurane was started for maintenance. Eight minutes into the procedure, the surgeon attempts to open the mouth and notes significant masseter muscle rigidity — the jaw is difficult to open despite apparently adequate anesthesia depth. The anesthesiologist is alerted. What is the most appropriate immediate interpretation of this finding and the initial clinical response?

• A) Masseter spasm after succinylcholine and sevoflurane is a normal pharmacological response in pediatric patients — children have higher succinylcholine receptor density in masseter fibers compared to adults, and this produces a prolonged contracture response; the finding is self-limiting and the procedure may continue without modification after the spasm resolves spontaneously in 3 to 5 minutes.
• B) Masseter spasm following succinylcholine administration in a patient receiving a volatile anesthetic is a recognized sentinel sign of possible malignant hyperthermia susceptibility — it represents an early manifestation of uncontrolled sarcoplasmic reticulum calcium release in the masseter muscle; the immediate response is to heighten vigilance, obtain urgent temperature and end-tidal CO2 trending data, prepare dantrolene for immediate administration, consider switching to total intravenous anesthesia, and notify the surgical team; the procedure should not continue without an explicit MH preparedness plan in place.
• C) Masseter spasm is a non-specific finding caused by inadequate depth of anesthesia rather than any pharmacological muscle effect; the correct response is to deepen anesthesia with additional sevoflurane and fentanyl; once adequate depth is achieved the masseter will relax and the procedure can continue; dantrolene is not indicated based on jaw stiffness alone.
• D) Masseter spasm after succinylcholine is caused by Phase II block affecting the jaw-closing muscles selectively — masseter fibers have a higher sensitivity to Phase II transition than other skeletal muscles; the appropriate response is to administer neostigmine 0.05 mg/kg to reverse the Phase II component in the masseter while monitoring for systemic Phase II block progression elsewhere.
• E) Masseter spasm is expected after the succinylcholine dose of 2 mg/kg in children — at this dose, the depolarizing contraction is more powerful in pediatric patients due to their higher nicotinic receptor density, and jaw stiffness lasting 5 to 10 minutes is within the normal range; the surgeon should be patient and attempt opening the mouth again once the succinylcholine block has fully worn off.

7. [CASE 2 — QUESTION 3] Continuing with the same patient. Sevoflurane was continued while the team discussed the masseter spasm. Over the next 12 minutes, end-tidal CO2 rises from 38 to 74 mmHg despite unchanged ventilator settings, temperature reaches 39.2°C, and generalized muscle rigidity is now visible across the limbs. Heart rate is 158 bpm and an arterial blood gas shows pH 7.12 with base deficit of −14. A full malignant hyperthermia crisis is now confirmed. Which of the following correctly describes the immediate pharmacological management priorities?

• A) Immediately discontinue sevoflurane and switch to a propofol-based total intravenous anesthetic; administer dantrolene 2.5 mg/kg intravenously and repeat every 5 minutes until clinical response (temperature declining, CO2 normalizing, rigidity resolving), with a total dose potentially exceeding 10 mg/kg; initiate active external cooling; manage hyperkalemia and acidosis supportively; call the MH hotline (1-800-MH-HYPER in North America); obtain creatine kinase and myoglobin levels and monitor for myoglobinuria and renal injury.
• B) Administer propofol 3 mg/kg as the primary treatment — propofol is a direct inhibitor of the ryanodine receptor calcium release channel at doses above 2 mg/kg/hr and constitutes both adequate anesthesia maintenance and targeted molecular treatment of the MH crisis; dantrolene should be held until propofol fails to normalize the temperature within 10 minutes.
• C) Administer succinylcholine 4 mg/kg to induce Phase II block, which will override the pathological ryanodine receptor calcium release by saturating end-plate nicotinic receptors and creating a sustained depolarization that prevents further action potential propagation to already-rigidly contracted muscle fibers; then discontinue sevoflurane.
• D) Administer neostigmine 0.07 mg/kg with glycopyrrolate — the muscular rigidity and hypermetabolism in MH are mediated through excessive acetylcholinesterase activity at the neuromuscular junction, causing sustained acetylcholine-driven contraction; neostigmine corrects this by inhibiting the excess acetylcholinesterase and normalizing synaptic acetylcholine turnover, reducing the hypermetabolic drive.
• E) Administer sodium bicarbonate 3 mEq/kg as the primary intervention — the metabolic acidosis (pH 7.12, base deficit −14) is the driver of the sustained sarcoplasmic reticulum calcium release in MH because acidosis activates the ryanodine receptor allosterically; correcting pH with bicarbonate will terminate calcium release and resolve the crisis within 5 to 10 minutes; dantrolene is a second-line agent for cases refractory to bicarbonate.

8. [CASE 2 — QUESTION 4] Continuing with the same patient. The MH crisis was successfully treated with dantrolene 7.5 mg/kg total dose. The patient recovered fully over 72 hours. The family is counseled and asks what this event means for the patient and his siblings. Which of the following best describes the appropriate post-crisis pharmacological and genetic counseling for this patient and his family?

• A) MH susceptibility in this patient is phenotypically confirmed by the crisis and requires no further genetic testing — the condition is environmentally acquired in some patients from early sevoflurane exposure during critical periods of neuromuscular development, so siblings who have not yet been exposed to volatile anesthetics have no inherent risk and do not require screening or modified anesthetic planning.
• B) The patient has confirmed MH susceptibility and should be referred for dibucaine number testing to characterize the severity of his ryanodine receptor variant; siblings with dibucaine numbers below 60 have co-segregating pseudocholinesterase deficiency that confirms MH susceptibility and should receive TIVA-only anesthesia for all future procedures.
• C) All first-degree relatives should immediately receive prophylactic dantrolene 2 mg/kg orally daily for 30 days to suppress ryanodine receptor sensitivity during the period when the genetic counseling and testing workup is ongoing; after genetic results confirm which relatives are susceptible, dantrolene prophylaxis is continued only in confirmed carriers.
• D) The patient's confirmed MH susceptibility means all future anesthetics must include dantrolene pretreatment — 2.5 mg/kg intravenously 30 minutes before induction — regardless of whether triggering agents are planned, because residual ryanodine receptor sensitization from prior exposure lowers the threshold for spontaneous crises with each subsequent exposure; siblings are not at risk unless they have also had a prior MH crisis.
• E) This patient has confirmed MH susceptibility by clinical crisis and should receive MH-safe anesthetic technique — total intravenous anesthesia with no volatile agents or succinylcholine — for all future procedures; all first-degree relatives (parents and siblings) are at risk because MH susceptibility follows autosomal dominant inheritance; relatives should be referred for caffeine-halothane contracture testing of a muscle biopsy or RYR1 gene sequencing to determine their susceptibility status before any elective anesthetic; the anesthetic team should document MH susceptibility prominently in all medical records.

9. [CASE 3 — QUESTION 1] A 47-year-old man was admitted to the ICU 18 days ago with rapidly progressive Guillain-Barré syndrome affecting all four limbs and the respiratory muscles. He has been mechanically ventilated since day 3 of admission and has significant bilateral limb weakness with areflexia on examination. He has had minimal voluntary movement of his extremities throughout the admission. His serum potassium today is 4.3 mEq/L. He has developed a mucus plug causing acute desaturation and requires urgent reintubation after the respiratory therapist accidentally dislodged his endotracheal tube during a repositioning procedure. A bedside nurse hands the physician a syringe labeled succinylcholine. Which of the following correctly identifies whether succinylcholine is appropriate and what the correct agent is?

• A) Succinylcholine is contraindicated in this patient — 18 days of peripheral nerve demyelination and functional denervation with complete immobility have provided more than sufficient time for extensive extrajunctional nAChR upregulation across the denervated muscle surface; administration of succinylcholine will trigger massive potassium efflux from these upregulated receptors, producing a serum potassium rise of 5 to 10 mEq/L or more that will cause ventricular fibrillation; the baseline potassium of 4.3 mEq/L provides no meaningful protection; rocuronium 1.2 mg/kg with sugammadex 16 mg/kg immediately available is the correct RSI agent.
• B) Succinylcholine is safe in this patient because the serum potassium is within normal limits at 4.3 mEq/L — life-threatening hyperkalemia from succinylcholine in neurological disease occurs only when the baseline potassium is already elevated above 5.5 mEq/L; the normal baseline provides sufficient buffer to absorb the expected 0.5 mEq/L rise without reaching the arrhythmic threshold.
• C) Succinylcholine is safe because Guillain-Barré syndrome causes demyelination of Schwann cells rather than axonal transection — the motor axon itself remains structurally intact, and extrajunctional receptor upregulation requires complete axonal transection to occur; GBS patients may receive succinylcholine safely throughout their illness because the trophic signals from the intact axon prevent receptor redistribution.
• D) Succinylcholine at a reduced dose of 0.5 mg/kg is appropriate — a lower dose limits the total potassium released per receptor by reducing the degree of membrane depolarization, making it safe in patients with partial extrajunctional receptor upregulation such as that seen in early-to-intermediate GBS; full upregulation requiring avoidance does not occur until 6 months after GBS onset.
• E) Succinylcholine is appropriate because the patient has been receiving continuous mechanical ventilation with induced pharmacological paralysis throughout the admission — pharmacological paralysis prevents the neural disuse that drives extrajunctional receptor upregulation; a patient who has been consistently paralyzed and ventilated has no greater succinylcholine risk than a neurologically intact patient.

10. [CASE 3 — QUESTION 2] Continuing with the same patient. Rocuronium 1.2 mg/kg was administered and reintubation was successful. The intensivist now asks whether standard rocuronium maintenance dosing can be used for this patient if ongoing neuromuscular blockade for ventilator synchrony is needed. Which of the following best characterizes the pharmacokinetic considerations that may alter rocuronium dosing requirements in a critically ill GBS patient?

• A) Rocuronium dosing is unaffected in GBS patients because the disease affects only the peripheral nervous system; since rocuronium's site of action is at the neuromuscular junction — a structure innervated by the peripheral motor nerve — the pharmacokinetics of the drug itself (volume of distribution, hepatic clearance, biliary excretion) are entirely determined by the patient's systemic physiology and are unrelated to the neurological diagnosis.
• B) Rocuronium should be increased by 30 to 40% above standard maintenance doses in GBS patients because extrajunctional receptor upregulation increases the total number of nicotinic receptors available for rocuronium binding, requiring a proportionally higher plasma concentration to achieve equivalent fractional receptor occupancy and the same depth of neuromuscular block.
• C) Rocuronium duration may be prolonged in this GBS patient for pharmacokinetic reasons independent of the neurological diagnosis itself — critical illness causes reduced hepatic blood flow and reduced hepatic metabolic capacity that slow rocuronium's primary biliary and hepatic elimination; 18 days of ICU care with potential autonomic instability, nutritional compromise, and fluid shifts can substantially reduce rocuronium clearance; maintenance doses should be guided by quantitative train-of-four monitoring rather than fixed time-based dosing, and doses should be reduced from standard intervals.
• D) Rocuronium is contraindicated for maintenance paralysis in GBS patients because the ongoing demyelination causes the motor nerve terminal to release abnormally high amounts of acetylcholine per impulse as a compensatory upregulation response; this excess acetylcholine competitively reverses rocuronium block within minutes of each dose, making maintenance paralysis pharmacologically impossible with any non-depolarizing agent.
• E) Rocuronium produces prolonged block in GBS patients specifically because the demyelinated peripheral nerve cannot generate the normal motor action potential needed to activate acetylcholinesterase at the neuromuscular junction; without acetylcholinesterase activity, rocuronium's competitive block cannot be modulated by normal synaptic acetylcholine dynamics and accumulates to supranormal receptor occupancy levels with each subsequent dose.

11. [CASE 3 — QUESTION 3] Continuing with the same patient. After reintubation, the intensivist decides that 48 to 72 hours of continuous neuromuscular blockade may be needed. On review of the chart, creatinine has risen to 2.9 mg/dL over the past 5 days, suggesting developing acute kidney injury likely from contrast given for a CT scan. The intensivist asks the clinical pharmacist which agent is preferable for prolonged ICU paralysis given the combined picture of critical illness, hepatic compromise, and now early renal impairment. Which of the following best identifies the most appropriate agent?

• A) Rocuronium infusion — its biliary excretion pathway is entirely independent of renal function, so the developing acute kidney injury will not affect its duration; the hepatic compromise seen in critical illness rarely reduces rocuronium clearance by more than 20%, which is clinically manageable with dose titration; its reversibility by sugammadex at any depth provides an additional safety advantage for ICU use.
• B) Vecuronium infusion — its active 3-desacetyl metabolite is predominantly eliminated by biliary excretion rather than renal excretion in critically ill patients with acute kidney injury because the liver upregulates biliary transport of the metabolite as a compensatory response to renal impairment; this adaptive response normalizes vecuronium duration in combined hepatorenal dysfunction.
• C) Pancuronium infusion — its long clinical duration reduces the frequency of re-dosing needed in an ICU paralysis protocol, minimizing nursing workload; its predominantly renal elimination means that the developing acute kidney injury will actually produce therapeutic drug accumulation, eliminating the need for active dose adjustment over the 48 to 72 hour paralysis period.
• D) Atracurium infusion — its dual Hofmann and ester hydrolysis elimination pathways are completely organ-independent and therefore unaffected by combined hepatic and renal compromise; it is preferred over cisatracurium for ICU use because its slightly faster Hofmann degradation rate produces a shorter context-sensitive half-time, allowing faster offset when the infusion is discontinued.
• E) Cisatracurium infusion — in a patient with combined hepatic compromise and developing acute kidney injury, organ-independent elimination is the essential selection criterion; cisatracurium's predominant Hofmann elimination pathway is unaffected by either hepatic or renal dysfunction, producing predictable duration regardless of organ failure; it is preferred over atracurium because it generates substantially less laudanosine per hour of infusion (due to its higher potency requiring lower drug mass) and produces minimal histamine release at clinical doses, making it the optimal agent for prolonged ICU paralysis in combined organ dysfunction.

12. [CASE 3 — QUESTION 4] Continuing with the same patient. Cisatracurium infusion was initiated and maintained for 60 hours. The infusion is now being weaned as the patient's pulmonary status improves. The team asks how to assess readiness for extubation from the neuromuscular perspective. Which of the following correctly describes the reversal strategy and monitoring requirements for this patient at the end of the cisatracurium infusion?

• A) Sugammadex 16 mg/kg should be administered immediately upon discontinuing the cisatracurium infusion to encapsulate and eliminate any remaining cisatracurium from the plasma, rapidly restoring full neuromuscular function and allowing immediate extubation assessment within 5 minutes.
• B) No pharmacological reversal is needed — cisatracurium's Hofmann elimination and ester hydrolysis pathways guarantee complete spontaneous recovery to TOF ratio above 0.9 within 30 minutes of infusion discontinuation regardless of infusion duration; quantitative monitoring is therefore unnecessary and extubation can proceed based on clinical assessment alone after a 30-minute waiting period.
• C) Neostigmine 0.07 mg/kg with glycopyrrolate should be given immediately upon infusion discontinuation — maximum-dose neostigmine will reverse cisatracurium block from any depth and is the standard reversal strategy for all benzylisoquinolinium agents at the end of ICU paralysis; it should be administered before the train-of-four count is checked to initiate reversal as soon as possible.
• D) Reversal of cisatracurium block at the end of ICU infusion requires quantitative train-of-four monitoring to determine the depth of residual block before any reversal strategy is applied — sugammadex cannot be used because cisatracurium is a benzylisoquinolinium without the steroidal scaffold for cyclodextrin encapsulation; if TOF count is ≥2, neostigmine 0.07 mg/kg with glycopyrrolate can be administered for pharmacological reversal, or spontaneous recovery via continued Hofmann elimination can be awaited; extubation should not proceed until quantitative TOF ratio confirms recovery above 0.9.
• E) Cisatracurium block at the end of a 60-hour infusion cannot be pharmacologically reversed by any available agent — the context-sensitive half-time after prolonged infusion is so extended that neither neostigmine nor sugammadex can achieve reversal within a clinically acceptable timeframe; the only management is continued mechanical ventilation for 4 to 6 hours until spontaneous Hofmann elimination reduces plasma concentrations below the block-sustaining threshold.

13. [CASE 4 — QUESTION 1] A 74-year-old woman with bilateral open-angle glaucoma has been using echothiophate iodide 0.06% ophthalmic drops in both eyes twice daily for 11 months to control her intraocular pressure. Her ophthalmologist did not communicate this medication to the anesthesia team when she was scheduled for cataract surgery. The anesthesiologist completes a medication reconciliation but does not recognize echothiophate as a relevant anesthetic concern. Succinylcholine 1.5 mg/kg is administered for intubation. Ninety minutes after the procedure, the patient remains apneic with a train-of-four count of zero. Which of the following correctly identifies the mechanism responsible for the prolonged block?

• A) Echothiophate is an anticholinergic agent used to reduce intraocular pressure by blocking muscarinic receptors in the ciliary body; systemic absorption from ophthalmic administration produces sustained anticholinergic effects throughout the body that competitively inhibit acetylcholinesterase at the neuromuscular junction, slowing acetylcholine breakdown and maintaining persistent end-plate depolarization from residual succinylcholine.
• B) Echothiophate is a long-acting organophosphate cholinesterase inhibitor that forms a covalent phosphoester bond with the active serine residue of cholinesterase enzymes; despite topical ophthalmic administration, clinically significant systemic absorption occurs via nasolacrimal drainage and conjunctival vasculature; after 11 months of twice-daily use, plasma pseudocholinesterase activity is abolished throughout the body; with no functional pseudocholinesterase available to hydrolyze succinylcholine, the drug persists in the plasma for hours, producing prolonged block indistinguishable from homozygous genetic pseudocholinesterase deficiency.
• C) Echothiophate blocks voltage-gated sodium channels in the perijunctional muscle membrane, preventing action potential propagation in the muscles of the eye following activation of the ciliary muscle; at the high doses produced by bilateral eye drop absorption over 11 months, the sodium channel blockade generalizes to skeletal muscle throughout the body, producing a combined succinylcholine-sodium channel block that is synergistically prolonged.
• D) Echothiophate raises intraocular acetylcholine levels by inhibiting ocular acetylcholinesterase; systemic absorption from bilateral eye drop use produces sufficient plasma concentrations to inhibit neuromuscular junction acetylcholinesterase throughout the body; with synaptic acetylcholine elevated from acetylcholinesterase inhibition, the end plate undergoes sustained acetylcholine-driven depolarization that transitions rapidly to Phase II block after succinylcholine administration, extending block duration from minutes to hours.
• E) Echothiophate potentiates succinylcholine block by competitively inhibiting the hepatic cytochrome P450 enzymes responsible for succinylcholine oxidative metabolism; in patients with bilateral echothiophate use, hepatic metabolism accounts for 60 to 70% of succinylcholine elimination; with both the hepatic and pseudocholinesterase pathways blocked simultaneously, the pharmacological half-life of succinylcholine extends to 3 to 5 hours.

14. [CASE 4 — QUESTION 2] Continuing with the same patient. The echothiophate use has now been identified. The anesthesiologist correctly diagnoses scoline apnea from echothiophate-mediated pseudocholinesterase inhibition. The patient is awake and aware, paralyzed and unable to communicate her distress. Which of the following correctly describes the immediate management priorities?

• A) Administer neostigmine 0.07 mg/kg with glycopyrrolate immediately — succinylcholine produces a depolarizing block and the standard reversal for this block type after prolonged duration is neostigmine; the drug's acetylcholinesterase inhibition will facilitate repolarization of the persistently depolarized end plate by increasing competition at muscarinic receptors that are maintaining the depolarization.
• B) Administer fresh frozen plasma 2 units intravenously — FFP contains functional pseudocholinesterase from donor plasma; two units of FFP will restore sufficient pseudocholinesterase activity to hydrolyze the remaining succinylcholine within 20 minutes, producing reliable recovery; this is the standard treatment for echothiophate-induced scoline apnea.
• C) Administer sugammadex 16 mg/kg — at 90 minutes, the prolonged succinylcholine block has transitioned to a Phase II state that has the pharmacological characteristics of competitive non-depolarizing block; sugammadex encapsulates molecules producing competitive-type block including Phase II succinylcholine derivatives, providing reversal within 3 minutes regardless of the underlying mechanism.
• D) Provide immediate adequate sedation with propofol or midazolam to prevent awareness — a paralyzed but conscious patient is experiencing extreme psychological distress; then maintain mechanical ventilation with appropriate monitoring until spontaneous neuromuscular recovery occurs as succinylcholine is cleared by very slow non-enzymatic degradation; do not administer neostigmine under any circumstances, as it will further inhibit any residual pseudocholinesterase and prolong the block; obtain neurology and pharmacology consultation; document the event and the echothiophate interaction prominently.
• E) Administer atropine 1 mg intravenously to block muscarinic overstimulation — the echothiophate-mediated cholinesterase inhibition has elevated systemic acetylcholine to levels that are maintaining persistent end-plate depolarization through direct muscarinic stimulation of the junctional region; blocking muscarinic receptors with atropine will interrupt the depolarizing input and allow the end plate to repolarize, restoring neuromuscular transmission within 10 minutes.

15. [CASE 4 — QUESTION 3] Continuing with the same patient. The patient recovers full neuromuscular function after 4 hours of ventilatory support. The anesthesiologist wants to determine whether the patient also has underlying genetic pseudocholinesterase deficiency in addition to the echothiophate inhibition, as this would affect future anesthetic planning. A dibucaine number is ordered. Which of the following correctly addresses the timing and interpretation of the dibucaine number in this clinical context?

• A) The dibucaine number should be drawn immediately — echothiophate inhibition does not affect dibucaine number interpretation because dibucaine inhibits the normal enzyme irreversibly while echothiophate inhibits it reversibly; the two inhibitors act at different sites on the enzyme and the dibucaine number will accurately reflect the structural genetic variant regardless of concurrent echothiophate effect.
• B) The dibucaine number drawn today will accurately reflect the patient's genetic enzyme phenotype — dibucaine acts on the residual uninhibited pseudocholinesterase fraction, so even with 90% of enzyme molecules inhibited by echothiophate, the dibucaine number calculated from the 10% residual activity will correctly identify the structural variant; a value above 70 indicates normal enzyme structure and a value below 40 indicates the atypical variant.
• C) The dibucaine number cannot be meaningfully interpreted while echothiophate inhibition is active — the test measures the percentage inhibition of plasma pseudocholinesterase by dibucaine, but with most or all enzyme molecules already irreversibly inhibited by echothiophate, there is insufficient active enzyme in the sample to generate a reliable signal; the test should be deferred for 4 to 6 weeks after echothiophate is discontinued to allow synthesis of new pseudocholinesterase enzyme with normal genetic configuration, at which point a valid dibucaine number can be measured.
• D) The dibucaine number is not an appropriate test for this patient regardless of timing — dibucaine numbers are only validated for patients of European descent; in patients of other ancestries the test produces inaccurate results because the atypical enzyme variant is distributed differently across ethnic groups and the standard dibucaine inhibition cutoffs do not apply.
• E) The dibucaine number should be drawn today and will reflect the genetic phenotype accurately — echothiophate inhibits the enzyme at the choline ester binding pocket while dibucaine inhibits at the anionic site; because the two inhibitors act at different catalytic sites, the echothiophate-inhibited molecules are still accessible to dibucaine at the anionic site, and the percentage inhibition by dibucaine correctly identifies the structural class of the enzyme independent of echothiophate occupancy.

16. [CASE 4 — QUESTION 4] Continuing with the same patient. The echothiophate has been discontinued and the ophthalmologist has switched her to a prostaglandin analog for glaucoma management. Six weeks later, a repeat dibucaine number returns at 78, confirming normal pseudocholinesterase enzyme structure. She now requires cataract surgery on the second eye. Which of the following best describes the safest approach to neuromuscular blocking agents for this second procedure?

• A) Succinylcholine should still be avoided as the primary intubating agent for this patient's future procedures — although her pseudocholinesterase activity has recovered and echothiophate has been discontinued, her prior prolonged apnea episode warrants a conservative approach; rocuronium 0.6 mg/kg for standard intubation with quantitative TOF monitoring and sugammadex availability is the preferred strategy; a thorough medication reconciliation confirming the absence of any cholinesterase-inhibiting agents should be documented before every anesthetic; if succinylcholine is ever used in the future, the team must be aware of the prior event even though the current dibucaine number is normal.
• B) Succinylcholine 1.5 mg/kg can be used without restriction — the dibucaine number of 78 confirms normal pseudocholinesterase structure and function; now that echothiophate has been discontinued and enzyme activity has fully recovered, there is no pharmacological reason to avoid succinylcholine; the prior prolonged block was entirely due to the echothiophate and will not recur with the glaucoma now managed by a non-cholinesterase-inhibiting agent.
• C) Succinylcholine is permanently contraindicated in this patient regardless of dibucaine number because one episode of prolonged succinylcholine block confirms an underlying genetic pseudocholinesterase mutation that the dibucaine number cannot detect — the normal dibucaine number of 78 represents the average of multiple enzyme subtypes, and a silent subpopulation of atypical molecules producing 15 to 20% of total activity can prolong block without being detected by standard dibucaine inhibition cutoffs.
• D) The patient should receive a general anesthetic technique using volatile agents at low concentration combined with a non-depolarizing NMBD — the prolonged prior block was due to echothiophate only, and now that this agent is discontinued, any standard technique with attention to medication reconciliation is appropriate; volatile agents specifically provide the benefit of muscle relaxation independent of any neuromuscular blocking agent, potentially eliminating the need for NMBD entirely.
• E) Succinylcholine should be replaced with mivacurium for all future anesthetic procedures — mivacurium is also hydrolyzed by pseudocholinesterase and its normal duration of 12 to 20 minutes confirms adequate enzyme activity at each use; the shorter duration of mivacurium compared to succinylcholine provides a built-in safety margin that limits total succinylcholine exposure.

17. [CASE 5 — QUESTION 1] A 61-year-old man with severe community-acquired pneumonia has been receiving a vecuronium infusion at 0.06 mg/kg/hour for 8 days to facilitate lung-protective ventilation for ARDS. His creatinine rose from 0.9 to 5.1 mg/dL over days 4 through 7, consistent with acute kidney injury from sepsis. The vecuronium infusion is discontinued on day 8 as his respiratory status improves. Forty hours later, the train-of-four count remains zero with no post-tetanic responses. Which of the following best identifies the pharmacological entity responsible for sustaining this profound block 40 hours after infusion discontinuation?

• A) Unchanged parent vecuronium — after 8 days of continuous infusion, the drug has saturated peripheral tissue compartments including the deep compartment of skeletal muscle; redistribution from these deep compartments back to the plasma and NMJ sustains block for 40 to 60 hours after discontinuation, a pharmacokinetic phenomenon proportional to the duration and dose of the infusion.
• B) Laudanosine — vecuronium undergoes minor Hofmann elimination at high ICU infusion doses, generating laudanosine that accumulates in renal failure; at the concentrations achieved after 8 days with a creatinine of 5.1 mg/dL, laudanosine reactivates nicotinic acetylcholine receptors at the NMJ by occupying the acetylcholine binding site as a partial agonist, maintaining depolarization-independent block.
• C) Succinylmonocholine — vecuronium at high prolonged doses undergoes non-enzymatic deacetylation to succinylmonocholine, a compound with both muscarinic and nicotinic activity; renal failure impairs its clearance, and accumulated succinylmonocholine transitions from muscarinic stimulation to sustained nicotinic end-plate depolarization at the concentrations achieved over an 8-day infusion.
• D) Pancuronium — vecuronium in renal failure is converted by renal tubular enzymes to pancuronium through an acetylation reaction that reverses the original monoquaternary synthesis; the resulting pancuronium has predominantly renal elimination and accumulates to neuromuscular blocking concentrations over the course of the infusion; this metabolic conversion explains why vecuronium in renal failure behaves pharmacokinetically like pancuronium.
• E) 3-Desacetyl-vecuronium — this pharmacologically active hepatic metabolite of vecuronium retains approximately 50% of the parent compound's neuromuscular blocking potency and is eliminated by renal excretion; with a creatinine of 5.1 mg/dL reflecting severely impaired renal clearance, the metabolite has accumulated progressively throughout the 8-day infusion to concentrations sufficient to sustain profound neuromuscular block at the train-of-four zero level for days after the vecuronium infusion is discontinued.

18. [CASE 5 — QUESTION 2] Continuing with the same patient. The intensivist considers administering sugammadex to reverse the accumulated 3-desacetyl-vecuronium block. A pharmacist advises that sugammadex should be effective. Which of the following correctly explains why sugammadex can reverse block sustained by an accumulated active vecuronium metabolite, and what dose is appropriate?

• A) Sugammadex is effective against 3-desacetyl-vecuronium because this metabolite retains the aminosteroid steroidal scaffold that is the structural basis for cyclodextrin encapsulation — the single deacetylation at the 3-position does not remove the steroidal ring system, leaving the molecular shape compatible with the sugammadex hydrophobic cavity; however, the binding affinity of sugammadex for 3-desacetyl-vecuronium is somewhat lower than for parent vecuronium, so a dose of 16 mg/kg is appropriate to ensure complete encapsulation of both residual parent drug and accumulated metabolite at profound block depth.
• B) Sugammadex cannot reverse 3-desacetyl-vecuronium block — the deacetylation at the 3-position removes a hydrophobic functional group that is required for insertion into the sugammadex cyclodextrin cavity; the metabolite binds to nicotinic receptors with its remaining potency but is pharmacologically excluded from sugammadex encapsulation; reversal must await spontaneous elimination of the metabolite, which requires renal function recovery.
• C) Sugammadex is effective because it works by competitive displacement rather than encapsulation — it competes with 3-desacetyl-vecuronium for the nicotinic receptor agonist binding site with higher affinity than the metabolite, producing functional receptor occupancy by a non-blocking compound that restores normal neuromuscular transmission; the effective dose for metabolite displacement is 4 mg/kg.
• D) Sugammadex works by pH-dependent precipitation of 3-desacetyl-vecuronium in the plasma — the cyclodextrin ring adjusts local pH around the steroidal metabolite, causing it to precipitate out of solution as an insoluble complex; the precipitate is then cleared by the reticuloendothelial system over 6 to 12 hours; this mechanism does not require renal function and is effective regardless of metabolite accumulation level.
• E) Sugammadex requires active renal function to be effective — after encapsulating 3-desacetyl-vecuronium, the sugammadex-metabolite complex must be excreted renally within 30 minutes or the complex dissociates and the released metabolite re-binds to neuromuscular junction receptors; in this patient with a creatinine of 5.1 mg/dL, sugammadex will produce only transient reversal followed by recurrent block within 60 to 90 minutes.

19. [CASE 5 — QUESTION 3] Continuing with the same patient. Sugammadex 16 mg/kg successfully reversed the block within 8 minutes. The intensivist decides the patient requires another 48 to 72 hours of neuromuscular blockade to continue lung-protective ventilation. Renal function has not recovered. Which agent should be used for the repeat ICU paralysis course?

• A) Vecuronium — now that the accumulated active metabolite has been cleared by sugammadex, restarting vecuronium at a lower infusion rate of 0.03 mg/kg/hour will limit metabolite generation to half the previous level; with quantitative TOF monitoring to guide dosing, vecuronium can be used safely even in ongoing renal failure.
• B) Rocuronium infusion with sugammadex 200 mg available at bedside for emergency reversal — rocuronium does not generate a renally cleared active metabolite and its biliary elimination pathway is unaffected by renal failure; in a patient with hepatic function preserved, rocuronium duration is predictable and it can be used safely with monitoring; the bedside sugammadex provides reversal reassurance.
• C) Pancuronium — its long duration reduces dosing frequency and nursing workload for an agent given over 48 to 72 hours; the accumulation from renal failure will be gradual and manageable with dose adjustment every 24 hours; the vagolytic tachycardia it produces will be beneficial in this septic patient who may have relative bradycardia.
• D) Cisatracurium — in a patient with ongoing acute kidney injury, any agent whose elimination depends on renal excretion (pancuronium) or that generates a renally eliminated active metabolite (vecuronium, 3-desacetyl metabolite) is inappropriate for repeat prolonged infusion; cisatracurium's Hofmann elimination is entirely independent of renal and hepatic function; it does not accumulate in organ failure and does not produce a pharmacologically active renally excreted metabolite; its minimal histamine release at clinical doses is an additional advantage in a hemodynamically unstable septic patient.
• E) Atracurium — its dual Hofmann and ester hydrolysis elimination is organ-independent; it is available at lower cost than cisatracurium and is therefore the more economical choice for a prolonged 48 to 72 hour infusion; the laudanosine and histamine concerns associated with atracurium are only clinically relevant at doses substantially above those needed for ICU paralysis.

20. [CASE 5 — QUESTION 4] Continuing with the same patient. Cisatracurium infusion was used for 65 hours and is now being weaned. Renal function has partially recovered with creatinine stabilizing at 2.8 mg/dL. Train-of-four count is currently 2 with significant fade. The team asks whether pharmacological reversal is appropriate at this point. Which of the following correctly applies the reversal pharmacology to this clinical scenario?

• A) Sugammadex 4 mg/kg is the correct agent — a TOF count of 2 with fade is classified as deep block; sugammadex 4 mg/kg is the dose for deep aminosteroid block and will reliably reverse the cisatracurium within 3 to 5 minutes, producing TOF ratio above 0.9 before proceeding to extubation assessment.
• B) No reversal agent is appropriate at TOF count 2 with fade — quantitative TOF monitoring must show spontaneous recovery to TOF ratio above 0.9 before any drug intervention or extubation assessment; pharmacological reversal agents are contraindicated during the spontaneous recovery phase of benzylisoquinolinium block.
• C) Neostigmine 0.07 mg/kg with glycopyrrolate is appropriate — a TOF count of 2 with fade indicates that spontaneous recovery has reached the minimum threshold for reliable neostigmine reversal (TOF count ≥2); neostigmine will competitively displace residual cisatracurium from end-plate receptors by raising synaptic acetylcholine concentration; glycopyrrolate is required to prevent bradycardia and excessive secretions from the increased muscarinic stimulation; TOF ratio should be confirmed above 0.9 before extubation assessment proceeds.
• D) Neostigmine is contraindicated at TOF count 2 because benzylisoquinolinium agents such as cisatracurium undergo spontaneous Hofmann elimination; administering neostigmine at this stage will inhibit the Hofmann degradation enzyme responsible for cisatracurium clearance, preventing further spontaneous recovery and paradoxically deepening the residual block; only spontaneous recovery is appropriate.
• E) Sugammadex 2 mg/kg is appropriate because the TOF count of 2 with fade identifies moderate block; however, because cisatracurium is a benzylisoquinolinium rather than an aminosteroid, the sugammadex dose must be doubled to 4 mg/kg to account for the lower binding affinity of cisatracurium's benzyl groups for the cyclodextrin cavity compared to the steroidal scaffold of rocuronium and vecuronium.

21. [CASE 6 — QUESTION 1] A 29-year-old woman at 33 weeks gestation is admitted with severe preeclampsia. She has been receiving magnesium sulfate 2 g/hour for 8 hours. Her serum magnesium is 5.4 mg/dL. She develops eclamptic seizures and requires intubation. The obstetric anesthesiologist performs RSI with succinylcholine 1.2 mg/kg (reduced from the standard 1.5 mg/kg given the magnesium) and achieves intubation. Rocuronium 0.1 mg/kg is given 10 minutes later for initial maintenance. Twelve minutes after the rocuronium dose, the train-of-four count drops to zero. Which of the following correctly explains this unexpectedly profound block from what would normally be a modest maintenance dose of rocuronium?

• A) The reduced succinylcholine RSI dose of 1.2 mg/kg produced insufficient initial block, leaving a significant fraction of nicotinic receptors unoccupied; the subsequent rocuronium 0.1 mg/kg occupied these remaining free receptors and together the two drugs produced complete receptor occupancy by additive binding at separate but synergistic sites on the nAChR.
• B) Magnesium potentiates non-depolarizing neuromuscular block by competing with calcium at presynaptic voltage-gated calcium channels, reducing acetylcholine release per nerve impulse; this reduced acetylcholine availability means less endogenous agonist is competing with rocuronium for receptor occupancy, shifting the rocuronium dose-response curve leftward; a dose of 0.1 mg/kg that would normally produce only moderate block (TOF count 2 to 3) in a patient without magnesium is sufficient to produce profound block (TOF count 0) when presynaptic acetylcholine release is already suppressed by therapeutic hypermagnesemia.
• C) The profound block results from a direct pharmacokinetic interaction — magnesium forms insoluble chelates with rocuronium in the plasma, preventing its biliary elimination and dramatically extending its plasma half-life; the prolonged plasma exposure from magnesium chelation raises the NMJ biophase concentration of rocuronium far above what the 0.1 mg/kg dose would normally produce.
• D) The profound block from 0.1 mg/kg rocuronium reflects the augmented nicotinic receptor density in the uterine and diaphragmatic muscles during pregnancy — pregnancy upregulates nAChR expression in smooth and striated muscle to support increased cardiac output demands; this higher receptor density means that a fixed dose of rocuronium occupies a smaller percentage of the total receptor pool but with greater pharmacological effect per molecule.
• E) The profound block occurred because succinylcholine 1.2 mg/kg in the presence of therapeutic magnesium produces Phase II block rather than Phase I block; Phase II block from succinylcholine converts the nicotinic receptor to a desensitized state that is hypersensitive to subsequent non-depolarizing agents, and the 0.1 mg/kg rocuronium produced profound block by acting on these already-desensitized receptors.

22. [CASE 6 — QUESTION 2] Continuing with the same patient. The cesarean delivery is proceeding. The magnesium infusion is continuing at 2 g/hour intraoperatively for ongoing seizure prophylaxis. The anesthesiologist needs to maintain adequate neuromuscular relaxation for the 45-minute procedure. Which of the following best describes the intraoperative neuromuscular blocking management strategy in this patient?

• A) Standard rocuronium redosing at 0.15 mg/kg every 30 minutes should be used — the magnesium interaction affects only the initial dose and its effect diminishes over time as magnesium redistributes from the neuromuscular junction; subsequent doses can be given at standard intervals without monitoring.
• B) The rocuronium infusion should be run at double the standard rate to overcome the magnesium competition — since magnesium is occupying presynaptic calcium channels and reducing acetylcholine release, a higher rocuronium concentration is needed to maintain the same competitive advantage over the reduced acetylcholine; doubling the infusion rate compensates for the magnesium effect mathematically.
• C) Neuromuscular blocking agents should be discontinued entirely for the remainder of the procedure — the profound block from the 0.1 mg/kg maintenance dose will persist for 60 to 90 minutes without additional dosing due to the magnesium potentiation; the surgical team should complete the procedure during this prolonged block period and no additional NMBD should be given.
• D) The magnesium infusion should be temporarily stopped for the duration of the surgical case and restarted in the post-anesthesia care unit — eliminating the magnesium interaction will normalize rocuronium pharmacodynamics to standard duration; this approach is safe because the half-life of serum magnesium after infusion discontinuation is approximately 5 to 7 hours, maintaining therapeutic levels throughout the procedure and postoperatively.
• E) Rocuronium maintenance doses should be substantially reduced from standard and administered only when quantitative train-of-four monitoring indicates return of at least one to two twitches — the continued magnesium infusion maintains presynaptic acetylcholine release suppression throughout the case, meaning that reduced doses will produce deeper and longer block than expected; TOF-guided dosing prevents inadvertent overdose and ensures adequate block without accumulation; if block becomes unexpectedly too deep, calcium gluconate 1 g IV can partially restore presynaptic calcium influx and increase acetylcholine release, modestly reversing the magnesium potentiation.

23. [CASE 6 — QUESTION 3] Continuing with the same patient. The cesarean section was completed and the patient was extubated in the operating room with a train-of-four count of 4 and apparent clinical recovery. She is now in the post-anesthesia care unit on 8 L/min oxygen with SpO₂ 88%. She cannot lift her head from the pillow, is drooling with pooling secretions, and has a weak cry when she attempts to cough. The magnesium infusion is still running at 2 g/hour postoperatively for continued seizure prophylaxis. Quantitative TOF monitoring shows a ratio of 0.68. Which of the following correctly identifies the cause and appropriate treatment?

• A) This patient has clinically significant residual neuromuscular block — the TOF ratio of 0.68 is well below the 0.9 threshold required for safe pharyngeal and airway protective function, and the ongoing magnesium infusion is sustaining the potentiation of residual rocuronium; sugammadex 2 mg/kg is appropriate (TOF count 4 with fade — moderate block range), will reliably reverse the residual aminosteroid block to TOF ratio above 0.9 within minutes, and is safe to use while the magnesium infusion continues because sugammadex acts by encapsulating rocuronium molecules, not by opposing the magnesium mechanism; the pharyngeal dysfunction and hypoxia will resolve as neuromuscular function is fully restored.
• B) The respiratory failure is caused by magnesium toxicity rather than residual neuromuscular block — serum magnesium levels above 5 mEq/L cause direct respiratory depression by crossing the blood-brain barrier and inhibiting central respiratory centers; the treatment is calcium gluconate 1 g intravenously to antagonize magnesium at central neural calcium channels, and the TOF ratio of 0.68 is a secondary finding that will normalize once central respiratory drive is restored.
• C) Neostigmine 0.07 mg/kg with glycopyrrolate is the appropriate reversal agent — it will raise synaptic acetylcholine to compete with residual rocuronium, and the concurrent magnesium infusion will augment neostigmine's effect by further blocking acetylcholinesterase in synergy; the combined neostigmine-magnesium cholinesterase inhibition will achieve full reversal more rapidly than neostigmine alone.
• D) The TOF ratio of 0.68 confirms adequate neuromuscular recovery — values above 0.6 are within normal limits for postoperative patients who have received magnesium; the respiratory failure is from pulmonary edema related to the preeclampsia and the fluid balance during the cesarean; diuresis with furosemide is the primary intervention.
• E) This patient requires immediate reintubation without reversal agent administration — the combined magnesium and residual rocuronium block is not pharmacologically reversible with any available agent; sugammadex cannot function in the presence of hypermagnesemia because magnesium displaces rocuronium from the cyclodextrin cavity, preventing encapsulation; the only management is airway control and waiting for spontaneous recovery.

24. [CASE 6 — QUESTION 4] Continuing with the same patient. She recovers fully after sugammadex 2 mg/kg. The attending anesthesiologist debriefs with residents. She emphasizes that the near-miss was caused by inadequate appreciation of the magnesium-rocuronium interaction at extubation. Which of the following best summarizes the pharmacological lesson and the preventive protocol for future obstetric cases involving magnesium and neuromuscular blocking agents?

• A) The lesson is that non-depolarizing agents should be avoided entirely in patients receiving therapeutic magnesium — the potentiation is too unpredictable to safely use any neuromuscular blocking agent; volatile anesthetics alone provide adequate muscle relaxation for cesarean delivery and eliminate the neuromuscular blocking drug risk.
• B) The lesson is that sugammadex 16 mg/kg should be administered prophylactically to all patients on magnesium therapy before extubation regardless of TOF ratio — this eliminates any possibility of residual rocuronium contributing to post-extubation respiratory failure; the risk of recurarization from incomplete cyclodextrin-rocuronium complex formation in hypermagnesemic patients justifies this precaution.
• C) The lesson is that neostigmine should replace sugammadex as the standard reversal agent in obstetric patients on magnesium — magnesium inhibits acetylcholinesterase, and adding neostigmine produces synergistic cholinesterase inhibition that overcomes the magnesium-enhanced block; the anti-muscarinic glycopyrrolate simultaneously blocks any excess muscarinic stimulation from both the magnesium and the neostigmine.
• D) The key pharmacological lessons are: therapeutic magnesium potentiates both succinylcholine and non-depolarizing block through presynaptic calcium channel inhibition, so maintenance doses must be reduced substantially from standard and administered based on TOF monitoring rather than fixed intervals; the magnesium interaction persists as long as the infusion continues, including postoperatively; quantitative TOF ratio measurement before extubation is mandatory in all patients receiving magnesium, and the 0.9 threshold applies equally regardless of concurrent medications; sugammadex reverses residual aminosteroid block fully in the presence of hypermagnesemia because its mechanism — rocuronium encapsulation — is independent of the magnesium-acetylcholine interaction; and the residual block may recur after extubation if the magnesium infusion continues and spontaneous recovery is relied upon without pharmacological confirmation.
• E) The key lesson is that the serum magnesium level should be reduced to below 3 mg/dL before any non-depolarizing agent is administered — levels below 3 mg/dL do not produce clinically significant presynaptic calcium channel inhibition; the anesthesiologist should request magnesium dose reduction from the obstetric team before induction and inform the team that standard NMBD dosing cannot be used at therapeutic magnesium levels.

25. [CASE 7 — QUESTION 1] A 58-year-old man undergoes emergency Hartmann procedure for perforated sigmoid colon. He received rocuronium 0.6 mg/kg at induction. The bowel is grossly contaminated and the surgeon irrigates the peritoneal cavity with 3 liters of neomycin solution. Within 10 minutes of beginning the irrigation, the train-of-four count drops from 3 to 0 and the patient develops complete diaphragmatic paralysis requiring manual ventilation. No additional neuromuscular blocking agent has been given. Which of the following correctly identifies the mechanism by which neomycin produced this profound intraoperative block?

• A) Neomycin competitively antagonizes acetylcholine at the postjunctional nicotinic acetylcholine receptor by occupying the agonist binding sites on the alpha subunits, producing additive competitive block with the residual rocuronium; the combined competitive occupancy from both agents drove receptor availability below the threshold for neuromuscular transmission.
• B) Neomycin absorbed through the peritoneal membrane inhibits plasma pseudocholinesterase by forming a stable carbamate complex, which prevents hydrolysis of the residual succinylcholine given for intubation; the accumulated succinylcholine produced persistent Phase I depolarizing block on top of the residual rocuronium, creating a composite block too deep for spontaneous recovery.
• C) Neomycin, like all aminoglycoside antibiotics, inhibits presynaptic voltage-gated calcium channels at the motor nerve terminal; absorbed through the large peritoneal surface area, it reached systemic concentrations sufficient to substantially reduce calcium influx per action potential, dramatically decreasing acetylcholine release per nerve impulse; with less acetylcholine available to compete with the residual rocuronium for receptor binding, the depth of block increased sharply from moderate to profound.
• D) Neomycin directly depolarizes the skeletal muscle sarcolemma by inserting into the lipid bilayer and forming cationic channels that allow sodium influx; the resulting depolarization inactivates voltage-gated sodium channels in the perijunctional membrane, preventing action potential propagation and producing a block additive with the competitive nicotinic antagonism of rocuronium.
• E) Neomycin inhibits acetylcholinesterase at the neuromuscular junction by forming a reversible competitive complex with the anionic site of the enzyme; elevated synaptic acetylcholine from this inhibition initially competes with and partially reverses the residual rocuronium block, but the rapidly rising acetylcholine concentration then desensitizes end-plate nicotinic receptors, producing a Phase II-like desensitization block that exceeds the competitive block and creates the profound paralysis observed.

26. [CASE 7 — QUESTION 2] Continuing with the same patient. At wound closure, the anesthesiologist administers neostigmine 0.07 mg/kg with glycopyrrolate. Fifteen minutes later, the TOF count is 1 with persistent fade. The block has not adequately reversed. The resident asks why neostigmine failed and what pharmacological agent might address the presynaptic component of the block. Which of the following correctly explains the neostigmine failure and identifies the rational adjunct?

• A) Neostigmine failed because the neomycin competitively occupies the nicotinic receptor at a site where acetylcholine cannot displace it at achievable concentrations; the rational adjunct is sugammadex 16 mg/kg, which encapsulates both neomycin and rocuronium simultaneously within the same cyclodextrin cavity, removing both blocking agents from the NMJ and restoring full neuromuscular transmission.
• B) Neostigmine failed because the neomycin is irreversibly bound to the presynaptic calcium channels, creating a permanent reduction in acetylcholine release that persists for the lifetime of the channel; no pharmacological adjunct can restore presynaptic function; the only management is intubation and ventilation until new calcium channel protein synthesis occurs over 5 to 7 days.
• C) Neostigmine failed because it paradoxically activated nicotinic autoreceptors on the presynaptic terminal, which are responsible for triggering acetylcholine exocytosis; by overstimulating these autoreceptors, neostigmine induced acetylcholine depletion from the presynaptic vesicle pool; the rational adjunct is atropine 2 mg to block the muscarinic component of this autoreceptor overstimulation and allow the vesicle pool to replenish.
• D) Neostigmine failed because its mechanism — raising synaptic acetylcholine by preventing its breakdown — cannot compensate for severely reduced acetylcholine release caused by neomycin's presynaptic calcium channel blockade; neostigmine acts postsynaptically on the enzyme that breaks down acetylcholine, but cannot increase how much acetylcholine is released; calcium gluconate 1 g intravenously is the rational adjunct because it competes with neomycin at presynaptic voltage-gated calcium channels, partially restoring calcium influx and increasing acetylcholine release, directly addressing the presynaptic component of the combined block.
• E) Neostigmine failed because the neomycin-induced block is a mixed depolarizing and non-depolarizing block — the calcium channel inhibition produces a depolarizing-like block at the presynaptic terminal that is worsened by acetylcholinesterase inhibition; the rational adjunct is Phase II block reversal with sugammadex 4 mg/kg, which reverses the Phase II component while neostigmine continues to address the non-depolarizing component.

27. [CASE 7 — QUESTION 3] Continuing with the same patient. Calcium gluconate 1 g was administered and 5 minutes later the TOF count improved to 2 with fade. The anesthesiologist now considers whether sugammadex can address the remaining block. Which of the following correctly explains how sugammadex would contribute in this situation and what dose is appropriate?

• A) Sugammadex is not appropriate in this scenario because the presynaptic neomycin block is still present — sugammadex removes rocuronium from the postsynaptic compartment, but the presynaptic calcium channel blockade will maintain reduced acetylcholine release indefinitely; restoring postsynaptic receptor availability without correcting the presynaptic deficit will not produce functional neuromuscular transmission.
• B) Sugammadex 4 mg/kg is appropriate at TOF count 2 with fade — it will directly encapsulate and remove the remaining rocuronium molecules from plasma and from the NMJ, eliminating the postsynaptic competitive antagonism component of the combined block; with rocuronium removed, the acetylcholine being released — even at the reduced level allowed by partial neomycin calcium channel blockade — will have full access to unblocked nicotinic receptors and can restore adequate neuromuscular transmission; the presynaptic neomycin effect will gradually resolve as the neomycin is eliminated over the subsequent hours.
• C) Sugammadex is not effective when calcium gluconate has already been administered — calcium gluconate forms stable complexes with the cyclodextrin molecule in the sugammadex structure, occupying the encapsulation cavity that would normally accommodate rocuronium; this calcium-cyclodextrin interaction reduces sugammadex efficacy by approximately 60 to 70% and makes the combination pharmacologically counterproductive.
• D) Sugammadex 16 mg/kg is required regardless of current TOF count because the neomycin interaction creates a non-linear pharmacokinetic profile for rocuronium that substantially increases the total rocuronium body burden beyond what standard dosing would produce; the higher dose of sugammadex is needed to encapsulate this excess drug load.
• E) Sugammadex should be withheld until the neomycin effect resolves spontaneously — the presynaptic block from neomycin will dissipate within 30 to 45 minutes as the drug is redistributed from the peritoneal compartment; once presynaptic acetylcholine release normalizes, the residual rocuronium block will spontaneously recover to TOF count 4, at which point standard sugammadex 2 mg/kg can be given based on the moderate block level.

28. [CASE 7 — QUESTION 4] Continuing with the same patient. Sugammadex 4 mg/kg was administered and the TOF ratio improved to 0.94 within 6 minutes. The patient was successfully extubated. In the debrief, the anesthesiologist explains why this case required more intensive monitoring than a standard rocuronium case and what principle governs neuromuscular monitoring when drug interactions are present. Which of the following best captures the pharmacological principle and clinical monitoring lesson?

• A) The key lesson is that aminoglycoside antibiotics should never be used for peritoneal irrigation in patients who have received neuromuscular blocking agents — alternative irrigation fluids such as povidone-iodine or saline should be used; if aminoglycoside irrigation is unavoidable, the neuromuscular blocking agent dose should be reduced to zero before irrigation begins and spontaneous recovery confirmed before proceeding.
• B) The key lesson is that calcium gluconate 1 g should be given prophylactically before any aminoglycoside administration in anesthetized patients to preload the presynaptic calcium channels and prevent the reduction in acetylcholine release that causes block deepening; prophylactic calcium gluconate prevents the interaction entirely and eliminates the need for additional monitoring.
• C) The key lesson is that drug interactions that deepen neuromuscular block are only clinically significant when the interaction agent is given intravenously — peritoneal absorption of aminoglycosides produces insufficient plasma concentrations to reach the motor nerve terminal in meaningful amounts; the profound block in this case was caused by an unrecognized second dose of rocuronium from a syringe mixup, not by the neomycin irrigation.
• D) The key lesson is that the TOF count is an adequate monitoring tool for cases with drug interactions — a TOF count of 4 at the end of any procedure confirms adequate recovery regardless of what drug interactions occurred during the case; the TOF ratio adds no additional clinical value when TOF count is already 4.
• E) The key pharmacological lesson is that when a drug interaction has occurred that deepens neuromuscular block beyond what the primary agent alone would produce, the monitoring standard does not change but its importance intensifies — TOF ratio must be confirmed above 0.9 at the adductor pollicis before extubation in every case, but in this case the consequence of relying on TOF count alone (which was 4 before extubation at the end of a standard rocuronium case) would have missed significant residual block from the combined interaction; quantitative TOF ratio measurement is the only reliable method to confirm that both the postsynaptic rocuronium component and any residual presynaptic acetylcholine release deficit have resolved sufficiently for safe pharyngeal and airway protective function; the TOF ratio of 0.94 achieved after calcium gluconate and sugammadex confirms the threshold was met.